Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Current Deferred Revenue (2019 - 2025)

Korro Bio (KRRO) has disclosed Current Deferred Revenue for 4 consecutive years, with $3.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Deferred Revenue rose 51.39% year-over-year to $3.3 million, compared with a TTM value of $3.3 million through Sep 2025, up 51.39%, and an annual FY2024 reading of $3.5 million, changed N/A over the prior year.
  • Current Deferred Revenue was $3.3 million for Q3 2025 at Korro Bio, down from $3.9 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $9.4 million in Q1 2021 and bottomed at $2.2 million in Q3 2024.
  • Average Current Deferred Revenue over 3 years is $4.2 million, with a median of $3.4 million recorded in 2024.
  • The sharpest move saw Current Deferred Revenue tumbled 75.65% in 2021, then surged 51.39% in 2025.
  • Year by year, Current Deferred Revenue stood at $9.4 million in 2021, then tumbled by 62.7% to $3.5 million in 2024, then fell by 5.15% to $3.3 million in 2025.
  • Business Quant data shows Current Deferred Revenue for KRRO at $3.3 million in Q3 2025, $3.9 million in Q2 2025, and $2.8 million in Q1 2025.